Interview with Sir Andrew Dillon, Chief Executive, National Institute for Health…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Address: National Institute for Health and Clinical Excellence
1st Floor
10 Spring Gardens
London
SW1A 2BU
Tel: +44 (0)845 003 7780
The National Institute for Health and Clinical Excellence (NICE) is an NHS organisation based in London and Manchester. NICE was set up on 1 April 1999 to ensure everyone has equal access to medical treatments and high quality care from the NHS – regardless of where they live in England and Wales.
Today NICE is recognised as being a world leader in setting standards for high quality healthcare and are the most prolific producer of clinical guidelines in the world. It also produces public health recommendations on how to help improve people’s health and prevent disease. These are aimed not just at the NHS but at local authorities and all those with a remit for improving people’s health in the public, private, community and voluntary sectors.
Topics covered by NICE’ guidance range from helping people to stop smoking and encouraging them to be more physically active through to the treatment of cancer, diabetes, musculoskeletal conditions and mental health problems. NICE also makes recommendations on the use of a range of drugs.
All its recommendations are devised by independent committees. NICE’s Citizens Council is the UK’s first advisory body made up entirely of members of the public.
NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages…
Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine…
Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, delves into the organization’s mission to transform dementia care through innovation, advocacy, and global collaboration. Carragher addresses critical challenges, including…
Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional…
The participation of Emma Walmsley, CEO of GlaxoSmithKline (GSK), in the FT Live Global Pharma and Biotech Summit coincided with the outcome of the American elections and the historic win…
A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern…
Medtech-focused recruitment consultant Ivor Campbell casts his eye over the profiles the global medtech industry needs most today. Campbell argues that while specialist scientists and engineers remain as important as…
The newly elected UK government’s Secretary of State for Health and Social Care Wes Streeting has a full plate of challenges ahead. Britain’s National Health Service (NHS) is plagued with…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
See our Cookie Privacy Policy Here
